CompletedPhase 1NCT05628883

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Studying Conjunctival malignant melanoma

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator: Amod Sarnaik, MD
Moffitt Cancer Center
Intervention: TBio-4101(biological)
Enrollment: 17 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2022 – 2026

Study locations (1)

Moffitt Cancer Center, Tampa, Florida, United States

Collaborators

Turnstone Biologics, Corp.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05628883 on ClinicalTrials.gov

Other trials for Conjunctival malignant melanoma

Additional recruiting or active studies for the same condition.

RECRUITINGNCT05797415
Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

See all trials for Conjunctival malignant melanoma →

← Back to all trials